Sign in
Back
Cost-effectiveness of Pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an italian national health service perspective
Journal article   Peer reviewed

Cost-effectiveness of Pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an italian national health service perspective

Stefano Capri, Camillo Porta and Thomas E. Delea
Clinical therapeutics, Vol.39(3, March 2017), pp.567-580.e2
2017
DOI: https://doi.org/10.doi.org/10.1016/j.clinthera.2017.01.017

Abstract

Cost-effectiveness analysis Partitioned survival analysis Renal cell carcinoma Utility values
A prior randomized controlled trial (COMPARZ [Comparing the Efficacy, Safety and Tolerability of Pazopanib versus Sunitinib]) found non-inferior progression-free survival for pazopanib versus sunitinib as first-line therapy in patients with advanced or metastatic renal cell carcinoma. The present study evaluated the cost-effectiveness of pazopanib versus sunitinib as first-line treatment for patients with metastatic renal cell carcinoma from an Italian National Health Service perspective.
pdf
9910010315798051261.69 MB
Published (Version of record)Ask the Library / Chiedi alla Biblioteca Restricted Access

Metrics

1 Record Views

Details